GPX3 and amyotrophic lateral sclerosis: While additional characterisation is still needed, i.e. larger studies may help elucidate the link between the causal SNP and GPX3, and/or in vivo models may investigate modulating its expression, our findings support it as a lead candidate relevant to understanding mechanisms of disease and therapy development in ALS.